Nebivolol Tarbis (Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, reducing heart rate and contractility, while simultaneously stimulating endothelial nitric‑oxide synthase. The increased nitric‑oxide release causes vasodilation of peripheral vessels, which together lower systemic vascular resistance and arterial blood pressure.

The appropriate dose of Nebivolol Tarbis is determined individually by the prescribing clinician based on the patient’s blood pressure, renal function, and overall clinical condition. Dosage adjustments may be required for special populations, and patients should follow the prescriber’s instructions precisely.

Safety data for nebivolol in pregnancy and lactation are limited, and the drug is generally classified as contraindicated or to be used only if the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative therapies with their healthcare provider.

To request Nebivolol Tarbis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with older non‑selective beta‑blockers, nebivolol offers β1‑selectivity and additional nitric‑oxide‑mediated vasodilation, which may result in fewer metabolic side effects and better tolerability. It is often preferred when clinicians seek a beta‑blocker that also improves endothelial function, though individual response varies.

Nebivolol Tarbis should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Nebivolol Tarbis is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water and avoid crushing or chewing unless specifically instructed.

The most serious adverse events include severe bradycardia, symptomatic hypotension, heart block, bronchospasm in patients with reactive airway disease, and rare cases of hepatic injury or allergic reactions. Patients should seek immediate medical attention if they experience fainting, chest pain, difficulty breathing, or signs of an allergic response.

Nebivolol is contraindicated in patients with known hypersensitivity to the drug, severe bradycardia, second‑ or third‑degree atrioventricular block, cardiogenic shock, or uncontrolled severe asthma. Caution is also advised for individuals with significant hepatic impairment or those taking medications listed under major interactions.